Hydrochlorothiazide Orifarm

Hydrochlorothiazide Orifarm is a prescription oral medication that contains the thiazide diuretic hydrochlorothiazide. It is marketed in the European Union and is supplied in tablet form (strength not specified). The product belongs to the antihypertensive and diuretic therapeutic classes and is used under medical supervision to manage fluid balance and blood pressure. It works by promoting urinary excretion of sodium and water, helping to reduce fluid accumulation in the body.

Hydrochlorothiazide Orifarm is indicated for several conditions where reduction of extracellular fluid volume or blood pressure control is required, and it is commonly prescribed as part of a broader therapeutic regimen. - Management of hypertension, either alone or combined with other antihypertensive agents. - Treatment of edema associated with congestive heart failure to relieve fluid overload. - Reduction of ascites and peripheral edema in patients with hepatic cirrhosis. - Control of swelling caused by renal disease, such as nephrotic syndrome. - Adjunct therapy for diuretic‑resistant edema when combined with loop diuretics.

Like other thiazide diuretics, Hydrochlorothiazide Orifarm may cause a range of adverse reactions, most of which are mild and reversible, while a few can be serious.

Common: - Increased urination (polyuria) and mild thirst. - Low blood potassium (hypokalemia) leading to muscle cramps or weakness. - Elevated blood glucose levels, especially in patients with diabetes. - Slight rise in blood uric acid, which may precipitate gout attacks. - Dizziness or light‑headedness due to volume depletion.

Serious: - Severe electrolyte disturbances such as hyponatremia or hypercalcemia. - Acute kidney injury manifested by sudden rise in serum creatinine. - Allergic reactions including rash, pruritus, or angioedema. - Pancreatitis, though rare, presenting with abdominal pain and nausea.

When prescribing Hydrochlorothiazide Orifarm, clinicians should evaluate patient history and monitor for conditions that may increase the risk of adverse events or reduce therapeutic benefit. - Assess renal function before initiation and periodically during therapy. - Monitor serum electrolytes, especially potassium, sodium, and calcium. - Use caution in patients with a history of gout or hyperuricemia. - Evaluate blood glucose levels in diabetic patients, as thiazides may raise glucose. - Avoid abrupt discontinuation to prevent sudden fluid and electrolyte shifts. - Consider dose adjustment in elderly patients due to increased sensitivity to volume depletion. - Discuss potential photosensitivity and advise sun protection.

Hydrochlorothiazide Orifarm can interact with several medicines, altering its diuretic effect or increasing the risk of electrolyte disturbances.

Avoid: - Concomitant use with lithium, which may raise lithium levels and cause toxicity. - Combination with other thiazide or loop diuretics without careful monitoring, risking severe volume depletion. - NSAIDs (e.g., ibuprofen, naproxen) that can blunt the diuretic response and impair renal function.

Use with caution: - ACE inhibitors, ARBs, or beta‑blockers, which may enhance antihypertensive effects and require blood pressure monitoring. - Antidiabetic agents, as thiazides can increase blood glucose, necessitating dose adjustments. - Anticoagulants, because volume changes may affect drug plasma concentrations.